Form 4: Rapport Therapeutics Director Receives Stock Option Grant

Director Wendy B. Young was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Wendy B. Young received a grant of 15,200 stock options for Rapport Therapeutics, Inc. (RAPP).
• The options have an exercise price of $35.21 per share.
• The grant was issued on June 10, 2026, with an expiration date of June 10, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $35.21 exercise price.

Future Outlook

The options vest on the earlier of June 10, 2027, or the date of the next Annual Meeting of Stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to attract and retain board expertise.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on June 10, 2027, or the next Annual Meeting of Stockholders.

Key Dates

Keywords

Rapport Therapeutics, RAPP, Form 4, Director Compensation, Stock Options, Insider Transaction